Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03173534 · ClinicalTrials.gov registry record · NA
WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement
A NA study, sponsored by samir kapadia.
- Completed
- Registry status
- NA
- Development phase
- 350
- Enrollment target
NCT03173534: Completed NA study, sponsored by samir kapadia.
NCT03173534 is a NA study that has completed, run by samir kapadia. The registered enrollment target is 350 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03173534, a NA study, has completed, sponsored by samir kapadia.
- COMPLETED
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
Study Summary
To evaluate the safety and effectiveness of the left atrial appendage occlusion with WATCHMAN Device in prevention of stroke and bleeding in patients with atrial fibrillation (AF) undergoing transcatheter aortic valve replacement (TAVR).
Primary Outcome
First occurrence of all-cause mortality, stroke (ischemic or hemorrhagic), or bleeding (life-threatening and major) events through 2 years post-randomization.
Interventions
- DEVICE TAVR
- DEVICE WATCHMAN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2022-12-06 |
| Phase | NA |
What the finished NCT03173534 record still lists
NCT03173534 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which TAVR is the first listed.
NCT03173534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03173534 about?
NCT03173534 is a clinical study titled "WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement". To evaluate the safety and effectiveness of the left atrial appendage occlusion with WATCHMAN Device in prevention of stroke and bleeding in patients with atrial fibrillation (AF) undergoing transcatheter aortic valve replacement (TAVR).
What is the current status of trial NCT03173534?
This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2017-12-15. Estimated completion is 2022-12-06.
What interventions are being tested in trial NCT03173534?
The interventions under investigation include: TAVR (DEVICE), WATCHMAN (DEVICE).
Who is sponsoring clinical trial NCT03173534?
This trial is sponsored by samir kapadia, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03173534's enrollment target sits among peer trials
350 292nd of 2000 higher than 1,699 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI